<The> sustained virologic response and adverse effects of peg interferon alfa and ribavirin in the treatment of patients with chronic hepatitis c: a study from Iran

Simin, Shoaei; Shahnaz, Sali; Azadeh, Lali; Mehdi, Karamipour; Javad, Minooeefar

sustained virologic response and adverse effects of peg interferon alfa and ribavirin in the treatment of patients with chronic hepatitis c: a study from Iran

Simin, Shoaei; Shahnaz, Sali; Azadeh, Lali; Mehdi, Karamipour; Javad, Minooeefar.

Novelty in Biomedicine. 2017; 5 (4): 172-176

en Inglés | IMEMR | ID: emr-189668

ABSTRACT

ABSTRACT

Background:

Hepatitis C infection is a worldwide problem. In Iran, hepatitis C virus [HCV] infection prevalence is about 1-2%. A combination therapy of pegylated interferon alfa-2a and ribavirin [PEG-IFNalpha/RBV] is a standard treatment, but our aim was to determine the efficacy and safety of dual PEG-IFNalpha/RBV therapy in treating patients infected with HCV in Iranian context

Asunto(s)

Humanos; Masculino; Femenino; Adulto; Interferón-alfa/efectos adversos; Ribavirina/efectos adversos; Quimioterapia Combinada; Factores de Riesgo; Estudios Transversales; Estudios Prospectivos

Buscar en Google

Imprimir

XML

Índice: IMEMR (Mediterraneo Oriental) Asunto principal: Ribavirina / Estudios Transversales / Estudios Prospectivos / Factores de Riesgo / Interferón-alfa / Quimioterapia Combinada Tipo de estudio: Estudio de prevalencia Límite: Adulto / Femenino / Humanos / Masculino Idioma: Inglés Revista: Novelty Biomed. Año: 2017

Similares

MEDLINE

LILACS

LIS

Buscar en Google

Imprimir

XML